Previous 10 | Next 10 |
CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it wi...
Cyclerion Therapeutics ( CYCN ) Q2 results : Revenues: $1.6M. More news on: Cyclerion Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Cyclerion Therapeutics (NASDAQ: CYCN ): Q2 GAAP EPS of -$1.18 misses by $0.34 . More news on: Cyclerion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– Two praliciguat Phase 2 studies for diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) on track for data readouts in Q4 2019 – – Phase 2 study of olinciguat in sickle cell disease on track for data readout in mid-2020 – ...
– Series of preclinical studies provide further rationale for study of IW-6463 as a potential treatment for neurodegenerative diseases – – Preclinical data provide insights int...
– In preclinical study, treatment with company’s investigational sGC stimulator olinciguat was associated with improved blood flow and reduced inflammation in a model of sickle cell disease – – New research supports the need for a novel patient-reporte...
Gainers: Genocea Biosciences (NASDAQ: GNCA ) +45% . Mirati Therapeutics (NASDAQ: MRTX ) +34% . Cypress Semiconductor (NASDAQ: CY ) +25% . ARCA biopharma (NASDAQ: ABIO ) +23% . Centrus Energy (NYSEMKT: LEU ) +18% . Spirit MTA REIT (NYSE: SMTA ) +18% . El Paso Electric (NYSE: EE ...
– Completed enrollment in Phase 2 studies of praliciguat in diabetic nephropathy and heart failure with preserved ejection fraction (HFpEF) – – Based on encouraging tolerability data, company intends to add a higher olinciguat dose level to the Phase 2 sickle c...
Cyclerion Therapeutics ( CYCN ) is a recent spin off from Ironwood Pharmaceuticals ( IRWD ) that caught my attention after President Mark Currie acquired over 270,000 shares (paid $14.81 for total of around $4 million). Keep in mind Mr. Currie already had received 51,648 shares via the actua...
CAMBRIDGE, Mass., April 25, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it wi...
News, Short Squeeze, Breakout and More Instantly...
Cyclerion Therapeutics Inc. Company Name:
CYCN Stock Symbol:
NYSE Market:
Cyclerion Therapeutics Inc. Website:
A look at the top 10 most actives in the United States Kazia Therapeutics Limited (KZIA) rose 248.0% to $0.6682 on volume of 430,252,408 shares Maxeon Solar Technologies Ltd. (MAXN) fell 15.0% to $0.2108 on volume of 237,403,092 shares NVIDIA Corporation (NVDA) rose 2.7% to $134.91 on vol...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 1.8% to $131.88 on volume of 307,014,213 shares SRIVARU Holding Limited (SVMH) rose 49.2% to $0.2275 on volume of 274,465,266 shares Nauticus Robotics Inc. (KITT) rose 19.6% to $0.192 on volume of 161,46...
Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) is one of today's top gainers. The company's shares have moved 37.28% on the day to $2.81. Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serio...